Literature DB >> 32649224

Multiparametric quantitative analysis of tumor perfusion and diffusion with 3T MRI: differentiation between benign and malignant soft tissue tumors.

Seul Ki Lee1, Won-Hee Jee2,3, Chan Kwon Jung4, Yang-Guk Chung5.   

Abstract

OBJECTIVE: To evaluate multiparametric MRI for differentiating benign and malignant soft tissue tumors.
METHODS: This retrospective study included 67 patients (mean age, 55 years; 18-82 years) with 35 benign and 32 malignant soft tissue tumors. Intravoxel incoherent motion diffusion-weighted imaging (IVIM-DWI)-derived parameters (D, D*, f), apparent diffusion coefficient (ADC), and dynamic contrast-enhanced (DCE)-MRI parameters (Ktrans, Kep, Ve, iAUC) were calculated. Myxoid and non-myxoid soft tissue tumors were divided for subgroup analysis. The parameters were compared between benign and malignant tumors.
RESULTS: ADC and D were significantly lower in malignant than benign soft tissue tumors (1170 ± 488 vs 1472 ± 349 µm2/s; 1132 ± 500 vs 1415 ± 374 µm2/s; p < 0.05). Ktrans, Kep, Ve, and iAUC were significantly different between malignant and benign soft tissue tumors (0.209 ± 0.160 vs 0.092 ± 0.067 min-1; 0.737 ± 0.488 vs 0.311 ± 0.230 min-1; 0.32 ± 0.17 vs 0.44 ± 0.28; 0.23 ± 0.14 vs 0.12 ± 0.09, p < 0.05, respectively). ADC (0.752), D (0.742), and Kep (0.817) had high AUCs. Subgroup analysis showed that only Ktrans, and iAUC were significantly different in myxoid tumors, while, ADC, D, Ktrans, Kep, and iAUC were significantly different in non-myxoid tumor for differentiating benign and malignant tumors. D, Kep, and iAUC were the most significant parameters predicting malignant soft tissue tumors.
CONCLUSION: Multiparametric MRI can be useful to differentiate benign and malignant soft tissue tumors using IVIM-DWI and DCE-MRI. ADVANCES IN KNOWLEDGE: 1. Pure tissue diffusion (D), transfer constant (Ktrans), rate constant (Kep), and initial area under time-signal intensity curve (iAUC) can be used to differentiate benign malignant soft tissue tumors.2. Ktrans and iAUC enable differentiation of benign and malignant myxoid soft tissue tumors.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32649224      PMCID: PMC8519635          DOI: 10.1259/bjr.20191035

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  27 in total

1.  Diffusion-weighted MRI in the characterization of soft-tissue tumors.

Authors:  Catherina S P van Rijswijk; Patrik Kunz; Pancras C W Hogendoorn; Antonïe H M Taminiau; Joost Doornbos; Johan L Bloem
Journal:  J Magn Reson Imaging       Date:  2002-03       Impact factor: 4.813

2.  Accuracy of MRI in characterization of soft tissue tumors and tumor-like lesions. A prospective study in 548 patients.

Authors:  Jan L M A Gielen; Arthur M De Schepper; Filip Vanhoenacker; Paul M Parizel; Xiaoling L Wang; Raf Sciot; Joost Weyler
Journal:  Eur Radiol       Date:  2004-07-29       Impact factor: 5.315

3.  Intravoxel incoherent motion imaging of tumor microenvironment in locally advanced breast cancer.

Authors:  E E Sigmund; G Y Cho; S Kim; M Finn; M Moccaldi; J H Jensen; D K Sodickson; J D Goldberg; S Formenti; L Moy
Journal:  Magn Reson Med       Date:  2011-02-01       Impact factor: 4.668

4.  Diagnostic performance of conventional MRI parameters and apparent diffusion coefficient values in differentiating between benign and malignant soft-tissue tumours.

Authors:  Y Song; Y C Yoon; Y Chong; S W Seo; Y-L Choi; I Sohn; M-J Kim
Journal:  Clin Radiol       Date:  2017-03-06       Impact factor: 2.350

5.  Soft tissue sarcoma: adding diffusion-weighted imaging improves MR imaging evaluation of tumor margin infiltration.

Authors:  Ji Hyun Hong; Won-Hee Jee; Chan-Kwon Jung; Joon-Yong Jung; Seung Han Shin; Yang-Guk Chung
Journal:  Eur Radiol       Date:  2018-11-09       Impact factor: 5.315

6.  MRI to differentiate benign from malignant soft-tissue tumours of the extremities: a simplified systematic imaging approach using depth, size and heterogeneity of signal intensity.

Authors:  W J Chung; H W Chung; M J Shin; S H Lee; M H Lee; J S Lee; M-J Kim; W K Lee
Journal:  Br J Radiol       Date:  2012-05-02       Impact factor: 3.039

7.  Use of diagnostic dynamic contrast-enhanced (DCE)-MRI for targeting of soft tissue tumour biopsies at 3T: preliminary results.

Authors:  Iris-Melanie Noebauer-Huhmann; Gabriele Amann; Martin Krssak; Joannis Panotopoulos; Pavol Szomolanyi; Michael Weber; Christian Czerny; Martin Breitenseher; Guenther Grabner; Wolfgang Bogner; Stefan Nemec; Martin Dominkus; Philipp Funovics; Reinhard Windhager; Siegfried Trattnig
Journal:  Eur Radiol       Date:  2015-01-11       Impact factor: 5.315

8.  Diffusion-weighted imaging of soft tissue tumors: usefulness of the apparent diffusion coefficient for differential diagnosis.

Authors:  Shuji Nagata; Hiroshi Nishimura; Masafumi Uchida; Jun Sakoda; Tatsuyuki Tonan; Kouji Hiraoka; Kensei Nagata; Jun Akiba; Toshi Abe; Naofumi Hayabuchi
Journal:  Radiat Med       Date:  2008-07-27

9.  Soft-tissue tumors: value of static and dynamic gadopentetate dimeglumine-enhanced MR imaging in prediction of malignancy.

Authors:  Catharina S P van Rijswijk; Maarje J A Geirnaerdt; Pancras C W Hogendoorn; Antonie H M Taminiau; Frits van Coevorden; Aeilko H Zwinderman; Thomas L Pope; Johan L Bloem
Journal:  Radiology       Date:  2004-09-30       Impact factor: 11.105

10.  Relationship between diffusion parameters derived from intravoxel incoherent motion MRI and perfusion measured by dynamic contrast-enhanced MRI of soft tissue tumors.

Authors:  Simona Marzi; Linda Stefanetti; Francesca Sperati; Vincenzo Anelli
Journal:  NMR Biomed       Date:  2015-11-25       Impact factor: 4.044

View more
  1 in total

1.  Diagnostic Performance of Diffusion MRI for differentiating Benign and Malignant Nonfatty Musculoskeletal Soft Tissue Tumors: A Systematic Review and Meta-analysis.

Authors:  Qian Wang; Xinguang Xiao; Yanchang Liang; Hao Wen; Xiaopeng Wen; Meilan Gu; Cuiping Ren; Kunbin Li; Liangwen Yu; Liming Lu
Journal:  J Cancer       Date:  2021-10-28       Impact factor: 4.207

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.